Skip to main content

P53 mutations in thyroid carcinoma: Tidings from an old foe

Journal of Endocrinological Investigation volume 24, pages 536–545 (2001)Cite this article

Abstract

The underlying mechanism leading to carcinogenesis involves genomic instability, likely related to aneuploidy. While p53 as a “guardian of the genome” is an appealing candidate as an initiator of genomic instability, its mutations or deletions usually occur late in the course of tumor progression. P53 may, however, become a target of events initiated by genomic instability. P53 is a transcription factor with multifaceted regulatory functions in the cell cycle, DNA repair and apoptosis. Inactivating p53 mutations have been described in some 50% of human cancers. These mutations are not only important in tumor progression but apparently also in the response of some tumors to chemotherapy and radiation treatment, thus to clinical outcome. P53 mutations are found in 14% of malignant thyroid tumors and are more frequent in poorly differentiated and anaplastic tumors. We have examined the mutation rates of p53 as a measure of genomic instability (hypermutability) of malignant thyroid tumors. We also wondered whether radiation enhances this tendency to genomic instability. To those ends we extracted all available entries from the p53 mutations database (http://www.perso@curies.fr), verified, extended where applicable, and supplemented that information from the original published reports. We were able to locate 100 entries. The distribution of the types of p53 aberrations in thyroid cancer was similar to those in the database as a whole. The silent mutation rate of 20%, not different from the expected 25%, is consistent with a random occurrence of these mutations. This silent mutation rate is 130 times that expected and is 7 times that of the p53 database. Moreover the distribution of p53 mutations is compatible with Poisson’s distribution, which, when considered in the context of the silent mutation rates, indicates that p53 is particularly hypermutable in thyroid cancer. Epigenetic deamination of CpG dinucleotides at highly transforming DNA-contact residues is a feature of poorly differentiated tumors and thus associated with tumor progression. The rates of p53 mutations in radiation-related thyroid cancers (15.4%) are similar to those in spontaneously arising tumors, although there was a highly significant heterogeneity (p<0.0005) in the residues mutated in the two tumor sets. None of the residues mutated in radiation-related thyroid cancer involved CpG deamination. Based on the evidence of p53 hypermutability, thyroid cancer appears to exhibit remarkable genomic instability. Spontaneous epigenetic mutational events are involved in tumor progression. While thyroid cancer related to radiation exposure does not increase the rates of p53 mutation, they exhibit mutation at residues not involved in p53/DNA interface.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. http://perso.curie.fr/Thierry.Soussi

  2. Vogelstein B., Lane D., Levine A.B. Surfing the p53 network. Nature 2000, 408: 307–310.

    PubMed  Article  CAS  Google Scholar 

  3. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 1999, 431: 199–209.

    PubMed  Article  CAS  Google Scholar 

  4. Franklin D.S., Godfrey V.L., O’Brien D.A., Deng C., Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol. 2000, 20: 6147–6158.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  5. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 2000, 10: 94–99.

    PubMed  Article  CAS  Google Scholar 

  6. Levine J.A. p53, the cellular gatekeeper for growth and cell division. Cell 1997, 88: 323–331.

    PubMed  Article  CAS  Google Scholar 

  7. Zhou B.-B., Elledge S.J. The DNA damage response: putting the checkpoints in perspective. Nature 2000, 408: 433–439.

    PubMed  Article  CAS  Google Scholar 

  8. Ohki R., Nemoto J., Murasawa H., Oda E., Inazawa J., Tanaka N., Taniguchi T. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J. Biol. Chem. 2000, 275: 22627–22630.

    PubMed  Article  CAS  Google Scholar 

  9. Chan T.A., Hermeking H., Lengauer C., Kinzler K.W., Vogelstein B. 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999, 401: 616–620.

    PubMed  Article  CAS  Google Scholar 

  10. Laronga C., Yang H.Y., Neal C., Lee M.H. Association of the cyclin-dependent kinases and the 14-3-3 sigma negatively regulates cell cycle progression. J. Biol. Chem. 2000, 275: 23106–23112.

    PubMed  Article  CAS  Google Scholar 

  11. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis 2000, 21: 485–495.

    PubMed  Article  CAS  Google Scholar 

  12. Hendrix M.J. De-mystifying the mechanism(s) of maspin. Nat. Med. 2000, 6: 374–376.

    PubMed  Article  CAS  Google Scholar 

  13. Shi Y., Zou M., Farid N.R., Al-Sediary S.T. Evidence of gene deletion of p21(WAF/CIPI), a cyclin-dependent protein kinase inhibitor in thyroid carcinomas. Br. J. Cancer 1996, 74: 1336–1341.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  14. Zou M., Shi Y., Al-Sediary S., Hussian S.S., Farid N.R. Expression of mdm-2 gene, a p53 binding protein in thyroid carcinogenesis. Cancer 1995, 76: 314–318.

    PubMed  Article  CAS  Google Scholar 

  15. Farid N.R. Pathogenesis of thyroid cancer: The significance of oncogenes, tumour suppressor genes and genomic instability. Exp. Clin. Endocrinol. Diabetes 1996, 104 (Suppl. 4): 1–12.

    PubMed  Article  CAS  Google Scholar 

  16. Shahedian B., Shi Y., Zou M., Farid N.R. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol. Genet. Metab. 2001, 72: 155–163.

    PubMed  Article  CAS  Google Scholar 

  17. Farid N.R., Shi Y., Zou M. Molecular basis of thyroid cancer. Endocr. Rev. 1994, 15: 202–232.

    PubMed  CAS  Google Scholar 

  18. Nakamura T., Yana I., Kobayashi T., Shin E., Karakawa K., Fujita S., Miya A., Mori T., Nishisho I., Takai S. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn. J. Cancer Res. 1992, 83: 1293–1298.

    Article  CAS  Google Scholar 

  19. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi T., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Unique association of p53 mutations with undifferentiated carcinoma but not with differentiated tumors of the thyroid gland. Cancer Res. 1992, 52: 1369–1371.

    PubMed  CAS  Google Scholar 

  20. Ito T., Seyama T., Mizuno T., Tsuyama N., Hayashi Y., Dohi K., Nakamura N., Akiyama M. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations. Jpn. J. Cancer Res. 1993, 84: 526–531.

    PubMed  Article  CAS  Google Scholar 

  21. Fagin J.A., Matuso K., Karmakar A., Chen D.L., Tang S.-H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993, 91: 179–184.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  22. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993, 91: 179–184.

    Article  Google Scholar 

  23. Zou M., Shi Y., Farid N.R. p53 mutations in all stages of thyroid carcinoma. J. Clin. Endocrinol. Metab. 1993, 77: 1054–1058.

    PubMed  CAS  Google Scholar 

  24. Dobashi Y., Sugimura H., Sakamoto A., Mernyei M., Mori M., Oyama T., Machinami R. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinoma. Diagn. Mol. Pathol. 1994, 3: 9–14.

    PubMed  Article  CAS  Google Scholar 

  25. Salvatore D., Celetti A., Fabien N., Paulin C., Martelli M.L., Battaglia C., Califano D., Monaco C., Vigietto G., Santoro M., Fusco A. Low frequency of p53 mutations in human thyroid tumours; p53 and Ras mutations in two out of fiftysix thyroid tumours. Eur. J. Endocrinol. 1996, 134: 177–183.

    PubMed  Article  CAS  Google Scholar 

  26. Hillebrandt S., Streffer C., Reiners C., Demidchik E. Mutations in p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Int. J. Radiat. Biol. 1996, 69: 39–45.

    PubMed  Article  CAS  Google Scholar 

  27. Zednius J., Larsson C., Wallin G., Backdahl M., Aspenblad U., Hoog A., Borresen A.L., Auer G. Alterations of p53 and expression of WAF/p21 in human thyroid tumors. Thyroid 1996, 6: 1–9.

    Article  Google Scholar 

  28. Nikiforov Y.E., Nikiforova M.N., Gnepp D.R., Fagin J.A. Prevalence of mutations of ras and p53 in benign and malignant tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 1996, 13: 687–693.

    PubMed  CAS  Google Scholar 

  29. Fogelfeld L., Bauer T.K., Schneider A.B., Swartz J.E., Zitman R. p53 gene mutations in radiation-induced thyroid cancer. J. Clin. Endocrinol. Metab. 1996, 81: 3039–3044.

    PubMed  CAS  Google Scholar 

  30. Ho Y.S., Tseng S.C., Chin T.Y. Hsieh L.L., Lin J.D. p53 gene mutations in thyroid carcinoma. Cancer Lett. 1996, 101: 85–92.

    Article  Google Scholar 

  31. Smida J., Zitzelsberger H., Kellerer A.M., Lehmann L., Minkus G., Negele T., Spelsberg F., Heiber L., Demidchik E.P., Lengfelder E., Bauchinger M. p53 mutations in childhood thyroid tumours from Belarus and in thyroid tumors without radiation history. Int. J. Cancer 1997, 73: 802–807.

    PubMed  Article  CAS  Google Scholar 

  32. Grebe S.K., McIver B., Hay I.D., Wu P.S., Maciel L.M., Drabkin H.A., Goellner J.R., Grant C.S., Jenkins R.B., Eberhardt N.L. Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggest involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 1997, 82: 3684–3691.

    PubMed  CAS  Google Scholar 

  33. Park K.Y., Koh J.M., Kim Y.I., Park H.J., Gong G., Hong S.J., Ahn I.M. Prevalences of Gsα, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in Korean population. Clin. Endocrinol. (Oxf.) 1998, 49: 317–323.

    Article  CAS  Google Scholar 

  34. Takeuchi Y., Daa T., Kashima K., Yokoyama S., Nakayama I., Noguchi S. Mutation of p53 in thyroid carcinoma with an insular component. Thyroid 1999, 9: 377–381.

    PubMed  Article  CAS  Google Scholar 

  35. Pisarchik A.V., Ermak, G., Kartel N.A., Figge J. Molecular alterations involving p53 codons 167 and 183 in papillary thyroid carcinoma from Chernobylcontaminated regions of Belarus. Thyroid 2000, 10: 25–30.

    PubMed  Article  CAS  Google Scholar 

  36. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54: 4855–4878.

    PubMed  CAS  Google Scholar 

  37. Boland C.R., Ricciardiello L. How many mutations does it take to make a tumor? Proc. Natl. Acad. Sci. USA 1999, 96: 14675–14677.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  38. Legnuar C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature 1998, 396: 643–649.

    Article  CAS  Google Scholar 

  39. Duesberg P., Stindl R., Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalysed by aneuploidy. Proc. Natl. Acad. Sci. USA 2000, 97: 14295–14300.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  40. Strauss B.S. Silent and multiple mutations in p53 and the question of the hypermutability of tumors. Carcinogenesis 1997, 18: 1445–1452.

    PubMed  Article  CAS  Google Scholar 

  41. Aguilar F., Harris C.C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264: 1317–1319.

    PubMed  Article  CAS  Google Scholar 

  42. Rodin S.I., Rodin A.S. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc. Natl. Acad. Sci. USA 1998, 95: 11927–11932.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  43. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor-suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265: 346–355.

    PubMed  Article  CAS  Google Scholar 

  44. Issa J.-P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., Baylin S.B. Methylation of the oestrogen receptor CpG islands links ageing and neoplasis in human colon. Nat. Genet. 1994, 7: 536–540.

    PubMed  Article  CAS  Google Scholar 

  45. Ahuja N., Li Q., Mohan A.L., Baylin S.B., Issa J.-P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res.1998, 58: 5489–5494.

    PubMed  CAS  Google Scholar 

  46. Loeb L.A. Microsatellite instability: marker of a mutated phenotype in cancer. Cancer Res. 1994, 54: 5059–5063.

    PubMed  CAS  Google Scholar 

  47. Tsao J.-L., Yatabe Y., Salovaara R., Jarvinen H.J., Mecklin J.-P., Aaltonan L.A., Tavare S., Shibata D. Genetic reconstruction of individual colorectal tumor histories. Proc. Natl. Acad. Sci. USA 2000, 97: 1236–1241.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  48. Gamble S.C., Cook M.C., Riches A.C., Herceg Z., Bryant P.E., Arrand J.E. p53 mutations in tumors derived from irradiated human thyroid epithelial cells. Mutat. Res. 1999, 425: 231–238.

    PubMed  Article  CAS  Google Scholar 

  49. Grollman A.P., Moriya M. Mutagenesis by 8-oxoguanine: an enemy within. Trends Genet. 1993, 9: 246–249.

    PubMed  Article  CAS  Google Scholar 

  50. Hussain S.P., Raja K., Amstad P.A., Sawyer M., Trudel L.J., Wogan G.N., Hofseth L.J., Shields P.G., Billiar T.R., Trautwien C., Hohler T., Galle P.R., Phillips D.H., Markin R., Marrogi A.J., Harris C.C. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases. Proc. Natl. Acad. Sci. USA 2000, 97: 12770–12775.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  51. Sera N., Ashizawa K., Ando T., Ide A., Abe Y., Usa T., Tominaga T., Ejima E., Hayashi T., Shimokawa I., Eguchi K. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy. Thyroid 2000, 10: 975–979.

    PubMed  Article  CAS  Google Scholar 

  52. Haugen B.R. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated. Thyroid 2000, 10: 971–973.

    PubMed  Article  CAS  Google Scholar 

  53. Brachmann R.K., Yu K., Eby Y., Pavletich N., Boeke J.D. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J. 1998, 17: 1847–1859.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  54. Wong K.-B., DeDecker B.S., Freund S.M.V., Proctor M.R., Bycroft M., Fersht A.R. Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 1999, 96: 8438–8442.

    PubMed Central  PubMed  Article  CAS  Google Scholar 

  55. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286: 2507–2510.

    PubMed  Article  CAS  Google Scholar 

  56. Qi J-S., Desai-Yajnik V., Yaun Y., Samuels H.H. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol. Cell. Biol. 1997, 17: 7195–7207.

    PubMed Central  PubMed  CAS  Google Scholar 

  57. Bhat M.K., Yu C.I., Zhan Q., Hayashi Y., Seth P., Cheng S.Y. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathway. J. Biol. Chem. 1997, 272: 28989–28993.

    PubMed  Article  CAS  Google Scholar 

  58. Qi J.S., Yuan Y., Desai-Yajanik V., Samuels H.H. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol. Cell Biol. 1999, 19: 864–872.

    PubMed Central  PubMed  CAS  Google Scholar 

  59. Puzianowska-Kuznicka M., Kamiya Y., Nauman A., Cheng S.-Y., Nauman J. Alteration of expression and impairment of function of the thyroid hormone receptor in human renal clear cell carcinoma (RCCC). Program of 12th International Thyroid Congress, Kyoto, October 22-27, 2000 p. 420 (Abstract).

    Google Scholar 

Download references

Author information

Affiliations

  1. Osancor Biotech Inc., 31 Woodland Drive, Watford, Herts, WD17 3BY, UK

    Nadir R. Farid

Authors
  1. Nadir R. Farid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nadir R. Farid.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Farid, N.R. P53 mutations in thyroid carcinoma: Tidings from an old foe. J Endocrinol Invest 24, 536–545 (2001). https://doi.org/10.1007/BF03343889

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343889

Key-words

  • Thyroid cancer
  • p53
  • mutations
  • genomic instability
  • radiation
  • epigenetic
  • CpG deamination
  • differentiation